239 related articles for article (PubMed ID: 37111316)
1. Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment.
Zhang K; Wang J; He Z; Qiu X; Sa R; Chen L
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111316
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation in human melanoma: past and future.
Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics in Cardiac Hypertrophy and Heart Failure.
Liu CF; Tang WHW
JACC Basic Transl Sci; 2019 Dec; 4(8):976-993. PubMed ID: 31909304
[TBL] [Abstract][Full Text] [Related]
4. The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review.
Rugo HS; Jacobs I; Sharma S; Scappaticci F; Paul TA; Jensen-Pergakes K; Malouf GG
Adv Ther; 2020 Jul; 37(7):3059-3082. PubMed ID: 32445185
[TBL] [Abstract][Full Text] [Related]
5. Epigenetics modifications and therapeutic prospects in human thyroid cancer.
Catalano MG; Fortunati N; Boccuzzi G
Front Endocrinol (Lausanne); 2012; 3():40. PubMed ID: 22649419
[TBL] [Abstract][Full Text] [Related]
6. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
7. Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma.
Hanly A; Gibson F; Nocco S; Rogers S; Wu M; Alani RM
JID Innov; 2022 Mar; 2(2):100090. PubMed ID: 35199090
[TBL] [Abstract][Full Text] [Related]
8. Advances in Epigenetic Cancer Therapeutics.
Hillyar C; Rallis KS; Varghese J
Cureus; 2020 Nov; 12(11):e11725. PubMed ID: 33391954
[TBL] [Abstract][Full Text] [Related]
9. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Cacabelos R
Drug Dev Res; 2014 Sep; 75(6):348-65. PubMed ID: 25195579
[TBL] [Abstract][Full Text] [Related]
10. New Approaches to Targeting Epigenetic Regulation in Bladder Cancer.
Thompson D; Lawrentschuk N; Bolton D
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980741
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
Chistiakov DA; Orekhov AN; Bobryshev YV
Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
[TBL] [Abstract][Full Text] [Related]
12. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
Anestopoulos I; Sfakianos AP; Franco R; Chlichlia K; Panayiotidis MI; Kroll DJ; Pappa A
Molecules; 2016 Dec; 22(1):. PubMed ID: 28042859
[TBL] [Abstract][Full Text] [Related]
13. Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.
Gelato KA; Adler D; Ocker M; Haendler B
Expert Opin Ther Targets; 2016 Jul; 20(7):783-99. PubMed ID: 26799480
[TBL] [Abstract][Full Text] [Related]
14. Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies.
Rubatto M; Borriello S; Sciamarrelli N; Pala V; Tonella L; Ribero S; Quaglino P
Melanoma Res; 2023 Dec; 33(6):462-474. PubMed ID: 37788101
[TBL] [Abstract][Full Text] [Related]
15. Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable
Mascaró C; Ortega A; Carceller E; Ruiz Rodriguez R; Ciceri F; Lunardi S; Yu L; Hilbert M; Maes T
J Biol Chem; 2019 May; 294(20):8311-8322. PubMed ID: 30804215
[TBL] [Abstract][Full Text] [Related]
16. Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg.
Fernández-Barrena MG; Arechederra M; Colyn L; Berasain C; Avila MA
JHEP Rep; 2020 Dec; 2(6):100167. PubMed ID: 33134907
[TBL] [Abstract][Full Text] [Related]
17. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
Patani N; Jiang WG; Newbold RF; Mokbel K
Anticancer Res; 2011 Dec; 31(12):4115-25. PubMed ID: 22199269
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
20. Epigenetics as a therapeutic target in breast cancer.
Connolly R; Stearns V
J Mammary Gland Biol Neoplasia; 2012 Dec; 17(3-4):191-204. PubMed ID: 22836913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
